JP2006514614A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006514614A5 JP2006514614A5 JP2004546183A JP2004546183A JP2006514614A5 JP 2006514614 A5 JP2006514614 A5 JP 2006514614A5 JP 2004546183 A JP2004546183 A JP 2004546183A JP 2004546183 A JP2004546183 A JP 2004546183A JP 2006514614 A5 JP2006514614 A5 JP 2006514614A5
- Authority
- JP
- Japan
- Prior art keywords
- activity
- assay
- enzyme
- hsd1
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000694 effects Effects 0.000 description 49
- 102000004169 proteins and genes Human genes 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 26
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 25
- 238000004166 bioassay Methods 0.000 description 25
- 230000003228 microsomal Effects 0.000 description 23
- 102000008645 11-beta-Hydroxysteroid Dehydrogenase Type 1 Human genes 0.000 description 20
- 108010088011 11-beta-Hydroxysteroid Dehydrogenase Type 1 Proteins 0.000 description 20
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 239000000758 substrate Substances 0.000 description 18
- 102000004190 Enzymes Human genes 0.000 description 16
- 108090000790 Enzymes Proteins 0.000 description 16
- 229960004544 cortisone Drugs 0.000 description 16
- 241000700159 Rattus Species 0.000 description 15
- 210000004185 Liver Anatomy 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 12
- 229960000890 hydrocortisone Drugs 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 11
- 210000001853 Microsomes, Liver Anatomy 0.000 description 10
- 235000019439 ethyl acetate Nutrition 0.000 description 10
- 239000007787 solid Substances 0.000 description 9
- 125000002009 alkene group Chemical group 0.000 description 8
- 102000004965 antibodies Human genes 0.000 description 8
- 108090001123 antibodies Proteins 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 8
- 238000001952 enzyme assay Methods 0.000 description 8
- -1 oxygen hydrocarbon Chemical class 0.000 description 8
- 210000001589 Microsomes Anatomy 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 125000001183 hydrocarbyl group Chemical group 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18β-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 6
- 239000004215 Carbon black (E152) Substances 0.000 description 6
- 210000003734 Kidney Anatomy 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 239000012131 assay buffer Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 230000001965 increased Effects 0.000 description 5
- 230000036715 Apparent Km Effects 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OBZHEBDUNPOCJG-WBXJDKIVSA-N Carbenoxolone Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCC(O)=O)C1(C)C OBZHEBDUNPOCJG-WBXJDKIVSA-N 0.000 description 3
- 229940073144 Glycyrrhetinic acid Drugs 0.000 description 3
- 206010022489 Insulin resistance Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 229960000530 carbenoxolone Drugs 0.000 description 3
- 230000024881 catalytic activity Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000001419 dependent Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229960003720 enoxolone Drugs 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000036962 time dependent Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 238000009010 Bradford assay Methods 0.000 description 2
- 206010012601 Diabetes mellitus Diseases 0.000 description 2
- XJLXINKUBYWONI-NNYOXOHSSA-N Nicotinamide adenine dinucleotide phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 201000001320 atherosclerosis Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000546 pharmaceutic aid Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 102000004277 11-beta-Hydroxysteroid Dehydrogenases Human genes 0.000 description 1
- 108090000874 11-beta-Hydroxysteroid Dehydrogenases Proteins 0.000 description 1
- OWSNXLPHOKXBBX-UHFFFAOYSA-N 2-N-phenylbenzene-1,2,4-triamine Chemical compound NC1=CC=C(N)C(NC=2C=CC=CC=2)=C1 OWSNXLPHOKXBBX-UHFFFAOYSA-N 0.000 description 1
- AMYCGTZQZUYICB-UHFFFAOYSA-N 2-[6-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-benzothiazol-2-yl]-N,N-diethylacetamide Chemical compound C1=C2SC(CC(=O)N(CC)CC)=NC2=CC=C1NS(=O)(=O)C1=CC=CC(Cl)=C1C AMYCGTZQZUYICB-UHFFFAOYSA-N 0.000 description 1
- LMIJHHNOLSGCFI-UHFFFAOYSA-N 2-[[6-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-benzothiazol-2-yl]sulfanyl]-N,N-diethylacetamide Chemical compound C1=C2SC(SCC(=O)N(CC)CC)=NC2=CC=C1NS(=O)(=O)C1=CC=CC(Cl)=C1C LMIJHHNOLSGCFI-UHFFFAOYSA-N 0.000 description 1
- SDRNNYJXRMLMIQ-UHFFFAOYSA-N 3-chloro-N,2-dimethyl-N-(3-methyl-2-oxo-1,3-benzothiazol-6-yl)benzenesulfonamide Chemical compound C=1C=C2N(C)C(=O)SC2=CC=1N(C)S(=O)(=O)C1=CC=CC(Cl)=C1C SDRNNYJXRMLMIQ-UHFFFAOYSA-N 0.000 description 1
- WVLMEXKPDOOWDU-UHFFFAOYSA-N 3-chloro-N-(1,2-dimethylbenzimidazol-5-yl)-2-methylbenzenesulfonamide Chemical compound C=1C=C2N(C)C(C)=NC2=CC=1NS(=O)(=O)C1=CC=CC(Cl)=C1C WVLMEXKPDOOWDU-UHFFFAOYSA-N 0.000 description 1
- GASJDYJSWXNTJU-UHFFFAOYSA-N 3-chloro-N-(2,3-dimethylbenzimidazol-5-yl)-2-methylbenzenesulfonamide Chemical compound C1=C2N(C)C(C)=NC2=CC=C1NS(=O)(=O)C1=CC=CC(Cl)=C1C GASJDYJSWXNTJU-UHFFFAOYSA-N 0.000 description 1
- ZYVQAIDSWNFREL-UHFFFAOYSA-N 3-chloro-N-(2,5-dimethyl-1,3-benzothiazol-4-yl)-2-methylbenzenesulfonamide Chemical compound CC1=CC=C2SC(C)=NC2=C1NS(=O)(=O)C1=CC=CC(Cl)=C1C ZYVQAIDSWNFREL-UHFFFAOYSA-N 0.000 description 1
- LNQWPSSYYDUERX-UHFFFAOYSA-N 3-chloro-N-(2,6-dimethyl-1,3-benzothiazol-7-yl)-2-methylbenzenesulfonamide Chemical compound C=12SC(C)=NC2=CC=C(C)C=1NS(=O)(=O)C1=CC=CC(Cl)=C1C LNQWPSSYYDUERX-UHFFFAOYSA-N 0.000 description 1
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 210000000577 Adipose Tissue Anatomy 0.000 description 1
- 208000002205 Allergic Conjunctivitis Diseases 0.000 description 1
- 206010001897 Alzheimer's disease Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000003455 Anaphylaxis Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 206010003816 Autoimmune disease Diseases 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 125000006414 CCl Chemical group ClC* 0.000 description 1
- 101700010451 CELB Proteins 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N Chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 Chloramphenicol Drugs 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 206010011401 Crohn's disease Diseases 0.000 description 1
- 210000000805 Cytoplasm Anatomy 0.000 description 1
- 206010061428 Decreased appetite Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 208000005679 Eczema Diseases 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- 101700041462 GUX2 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000007565 Gingivitis Diseases 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 229940045189 Glucose-6-Phosphate Drugs 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N Glucose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 208000005721 HIV Infections Diseases 0.000 description 1
- 206010018987 Haemorrhage Diseases 0.000 description 1
- 210000003494 Hepatocytes Anatomy 0.000 description 1
- 210000001320 Hippocampus Anatomy 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108060001084 Luciferase family Proteins 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 102100008175 MGAM Human genes 0.000 description 1
- 206010026673 Malignant pleural effusion Diseases 0.000 description 1
- 230000036650 Metabolic stability Effects 0.000 description 1
- 206010027476 Metastasis Diseases 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 206010027599 Migraine Diseases 0.000 description 1
- 208000008085 Migraine Disorders Diseases 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- 208000003067 Myocardial Ischemia Diseases 0.000 description 1
- AEUCZQDDOWUIAW-UHFFFAOYSA-N N-(2-methyl-1-phenylbenzimidazol-5-yl)acetamide Chemical compound CC1=NC2=CC(NC(=O)C)=CC=C2N1C1=CC=CC=C1 AEUCZQDDOWUIAW-UHFFFAOYSA-N 0.000 description 1
- 229940097496 Nasal Spray Drugs 0.000 description 1
- 231100000618 Neurotoxin Toxicity 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 210000001525 Retina Anatomy 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- 206010039083 Rhinitis Diseases 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N Rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229940043267 Rhodamine B Drugs 0.000 description 1
- 101700061430 SAT19 Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 101700081234 TTR Proteins 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 206010068760 Ulcers Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 150000001336 alkenes Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000001837 anti-cortisol Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000004421 aryl sulphonamide group Chemical group 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000000740 bleeding Effects 0.000 description 1
- 231100000319 bleeding Toxicity 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000006474 brain ischemia Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 230000000271 cardiovascular Effects 0.000 description 1
- 230000003197 catalytic Effects 0.000 description 1
- 101700046922 cex Proteins 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229910021320 cobalt-lanthanum-strontium oxide Inorganic materials 0.000 description 1
- 201000006233 congestive heart failure Diseases 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 108091007687 cortisol binding proteins Proteins 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 201000004624 dermatitis Diseases 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 231100001003 eczema Toxicity 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 201000009273 endometriosis Diseases 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- BJOVOWDUSPGFTN-UHFFFAOYSA-N ethyl 2-[[6-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-benzothiazol-2-yl]sulfanyl]acetate Chemical compound C1=C2SC(SCC(=O)OCC)=NC2=CC=C1NS(=O)(=O)C1=CC=CC(Cl)=C1C BJOVOWDUSPGFTN-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 125000005842 heteroatoms Chemical group 0.000 description 1
- 201000001820 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 230000002045 lasting Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000003211 malignant Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 201000009906 meningitis Diseases 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000001537 neural Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000001184 potassium carbonate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 200000000008 restenosis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 230000037327 stress response Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 201000006704 ulcerative colitis Diseases 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0224830.0A GB0224830D0 (en) | 2002-10-24 | 2002-10-24 | Compound |
US43663502P | 2002-12-30 | 2002-12-30 | |
PCT/GB2003/004590 WO2004037251A1 (en) | 2002-10-24 | 2003-10-23 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006514614A JP2006514614A (ja) | 2006-05-11 |
JP2006514614A5 true JP2006514614A5 (de) | 2006-10-12 |
Family
ID=32178879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004546183A Pending JP2006514614A (ja) | 2002-10-24 | 2003-10-23 | 11β−ヒドロキシステロイドデヒドロゲナーゼ1型および2型のインヒビター |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1556040A1 (de) |
JP (1) | JP2006514614A (de) |
KR (1) | KR20050059294A (de) |
AU (1) | AU2003274373A1 (de) |
BR (1) | BR0315605A (de) |
CA (1) | CA2501228A1 (de) |
MX (1) | MXPA05004434A (de) |
NO (1) | NO20052469L (de) |
PL (1) | PL376301A1 (de) |
WO (1) | WO2004037251A1 (de) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0302572D0 (sv) * | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
SE0302570D0 (sv) * | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
GB0408771D0 (en) * | 2004-04-20 | 2004-05-26 | Sterix Ltd | Compound |
US20100222316A1 (en) | 2004-04-29 | 2010-09-02 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US8415354B2 (en) | 2004-04-29 | 2013-04-09 | Abbott Laboratories | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US7880001B2 (en) | 2004-04-29 | 2011-02-01 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
DE102004047272A1 (de) * | 2004-09-24 | 2006-04-06 | Schering Ag | Inhibitoren der löslichen Adenylatzyklase |
CN102816081A (zh) | 2005-01-05 | 2012-12-12 | 雅培制药有限公司 | 11-β-羟甾类脱氢酶1型酶的抑制剂 |
US8198331B2 (en) | 2005-01-05 | 2012-06-12 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US20090192198A1 (en) | 2005-01-05 | 2009-07-30 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US7511175B2 (en) | 2005-01-05 | 2009-03-31 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
WO2006097337A2 (en) * | 2005-03-18 | 2006-09-21 | Onepharm Gmbh | 11β-HYDROXYSTEROID DEHYDROGENASES |
WO2006105127A2 (en) * | 2005-03-31 | 2006-10-05 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
US7786137B2 (en) * | 2005-05-10 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Bicyclic derivatives as modulators of ion channels |
CN101263112B (zh) | 2005-07-01 | 2012-10-10 | 伊莱利利公司 | 组胺h3受体药物、其制备和治疗用途 |
US7622492B2 (en) | 2005-08-31 | 2009-11-24 | Hoffmann-La Roche Inc. | Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase |
US7825122B2 (en) | 2005-12-14 | 2010-11-02 | Amgen Inc. | Diaza heterocyclic sulfonamide derivatives and their uses |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
WO2008017381A1 (de) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
DE102007005045B4 (de) | 2007-01-26 | 2008-12-18 | Sanofi-Aventis | Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE102007012284A1 (de) * | 2007-03-16 | 2008-09-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
JP5736098B2 (ja) | 2007-08-21 | 2015-06-17 | アッヴィ・インコーポレイテッド | 中枢神経系障害を治療するための医薬組成物 |
DE102008019838A1 (de) * | 2008-04-19 | 2009-12-10 | Boehringer Ingelheim International Gmbh | Neue Arylsulfonylglycin-Derivate, deren Herstellung und deren Verwendung als Arzneimittel |
AR072707A1 (es) | 2008-07-09 | 2010-09-15 | Sanofi Aventis | Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos |
US20100022572A1 (en) | 2008-07-18 | 2010-01-28 | Kowa Company, Ltd. | Novel spiro compound and medicine comprising the same |
TW201010975A (en) | 2008-08-29 | 2010-03-16 | Kowa Co | 1-adamantylazetidin-2-one derivatives and drugs containing same |
MX2011004258A (es) | 2008-10-22 | 2011-06-01 | Merck Sharp & Dohme | Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos. |
US8252781B2 (en) | 2008-10-29 | 2012-08-28 | Kowa Company, Ltd. | 1,2-diazetidin-3-one derivatives and drugs containing same |
JP5557845B2 (ja) | 2008-10-31 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体 |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
WO2010118063A2 (en) | 2009-04-06 | 2010-10-14 | Agios Pharmaceuticals, Inc. | Therapeutic compositions and related methods of use |
ES2619557T3 (es) * | 2009-05-04 | 2017-06-26 | Agios Pharmaceuticals, Inc. | Activadores de PKM2 para uso en el tratamiento del cáncer |
WO2011002817A1 (en) | 2009-06-29 | 2011-01-06 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
DK2448581T3 (en) | 2009-06-29 | 2017-03-13 | Agios Pharmaceuticals Inc | Therapeutic compositions and methods for their applications |
CA2771278A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
WO2012042915A1 (en) * | 2010-10-01 | 2012-04-05 | Raqualia Pharma Inc. | Sulfamoyl benzoic acid heterobicyclic derivatives as trpm8 antagonists |
US9221792B2 (en) | 2010-12-17 | 2015-12-29 | Agios Pharmaceuticals, Inc | N-(4-(azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase M2 (PMK2) modulators |
MX336022B (es) | 2010-12-21 | 2016-01-06 | Agios Pharmaceuticals Inc | Activadores de pkm2 bicíclicos. |
TWI549947B (zh) | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
EP3243385B1 (de) | 2011-02-25 | 2021-01-13 | Merck Sharp & Dohme Corp. | Neue cyclische azabenzimidazolderivate als antidiabetika |
US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
US8846666B2 (en) | 2011-03-08 | 2014-09-30 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2683703B1 (de) | 2011-03-08 | 2015-05-27 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
ES2675903T3 (es) | 2011-05-03 | 2018-07-13 | Agios Pharmaceuticals, Inc. | Activadores de piruvato quinasa para uso en terapia |
WO2012151440A1 (en) | 2011-05-03 | 2012-11-08 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
AU2013296470B2 (en) | 2012-08-02 | 2016-03-17 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
EP3309166A3 (de) * | 2013-01-23 | 2018-08-22 | Sphaera Pharma Pvt. Ltd. | 11-beta-hydroxy-steroiden zur verwendung bei einer mitochondrien-biogenese und krankheiten im zusammenhang mit mitochondriendysfunktion oder -abreicherung |
EP2958562A4 (de) | 2013-02-22 | 2016-08-10 | Merck Sharp & Dohme | Antidiabetische bicyclische verbindungen |
US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
EP3171855B1 (de) | 2014-07-23 | 2020-08-26 | Sphaera Pharma Pvt. Ltd. | 11.beta.-hydroxysteroid-4-aza-verbindungen, zusammensetzungen und verwendungen davon |
MX2017016041A (es) | 2015-06-11 | 2018-04-24 | Agios Pharmaceuticals Inc | Metodos para usar activadores de piruvato cinasa. |
EP3551176A4 (de) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | Antidiabetische heterocyclische verbindungen |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
CN111479805A (zh) | 2017-08-29 | 2020-07-31 | 罗格斯新泽西州立大学 | 治疗性吲唑 |
WO2020120576A1 (en) * | 2018-12-11 | 2020-06-18 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | p38α AUTOPHOSPHORYLATION INHIBITORS |
KR102433502B1 (ko) * | 2020-01-17 | 2022-08-18 | 재단법인 대구경북첨단의료산업진흥재단 | 신규 화합물, 이의 제조방법 및 이의 용도 |
WO2023236920A1 (en) * | 2022-06-07 | 2023-12-14 | Sironax Ltd. | Sarm1 modulators, preparations, and uses thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
JPS62207271A (ja) * | 1986-03-06 | 1987-09-11 | Yamanouchi Pharmaceut Co Ltd | 2−ピリジルメチルチオ基または2−ピリジルメチルスルフイニル基で置換された縮合環化合物 |
JPS6355543A (ja) * | 1986-08-26 | 1988-03-10 | Konica Corp | 発汗現象及びスタチツクマ−ク発生を防止したハロゲン化銀写真感光材料 |
KR100225087B1 (ko) | 1990-03-23 | 1999-10-15 | 한스 발터라벤 | 피타아제의 식물내 발현 |
GB9020338D0 (en) * | 1990-09-18 | 1990-10-31 | Lilly Industries Ltd | Pharmaceutical compounds |
AU4700896A (en) * | 1995-01-20 | 1996-08-07 | G.D. Searle & Co. | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors |
TWI242011B (en) * | 1997-03-31 | 2005-10-21 | Eisai Co Ltd | 1,4-substituted cyclic amine derivatives |
ATE284387T1 (de) * | 1998-10-08 | 2004-12-15 | Smithkline Beecham Plc | 3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3) |
SE0001899D0 (sv) | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
US6849622B2 (en) * | 2000-10-06 | 2005-02-01 | Tanabe Seiyaku Co., Ltd. | Aliphatic nitrogenous five-membered ring compounds |
JP5145624B2 (ja) * | 2000-12-22 | 2013-02-20 | コニカミノルタホールディングス株式会社 | シラノール基含有記録媒体用インク、ポリマー粒子の水分散体及びインクジェット記録用水系インク |
-
2003
- 2003-10-23 KR KR1020057007048A patent/KR20050059294A/ko not_active Application Discontinuation
- 2003-10-23 EP EP03758357A patent/EP1556040A1/de not_active Withdrawn
- 2003-10-23 PL PL03376301A patent/PL376301A1/xx not_active Application Discontinuation
- 2003-10-23 MX MXPA05004434A patent/MXPA05004434A/es unknown
- 2003-10-23 JP JP2004546183A patent/JP2006514614A/ja active Pending
- 2003-10-23 CA CA002501228A patent/CA2501228A1/en not_active Abandoned
- 2003-10-23 AU AU2003274373A patent/AU2003274373A1/en not_active Abandoned
- 2003-10-23 WO PCT/GB2003/004590 patent/WO2004037251A1/en active Application Filing
- 2003-10-23 BR BR0315605-2A patent/BR0315605A/pt not_active IP Right Cessation
-
2005
- 2005-05-23 NO NO20052469A patent/NO20052469L/no not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2006514614A5 (de) | ||
EP0931060B1 (de) | Substituierte n-(aminoiminomethyl oder aminomethyl)phenyl propylamide | |
US6300364B1 (en) | Medicinal compositions with cholesterol-lowering effect | |
EP3348557B1 (de) | Imidazo[1,2a]pyridine zur behandlung oder prävention von hyperurikämie oder gicht | |
EP1569924A2 (de) | Nf-kb-inhibitoren | |
EP0112623A2 (de) | 3-Aryl-5-Pyrazol-Carboxyl-Säure-Derivate, ihre Herstellung und pharmazeutische Zusammensetzungen | |
JP7092742B2 (ja) | ケモカインの生物活性を中和するためのピリミジノン誘導体およびその使用 | |
RU2282627C2 (ru) | Кумариновые производные с подавляющей комт активностью | |
JP2000507971A (ja) | 3−アミノ−1,2−ベンゾイソオキサゾール誘導体類とその製造方法及び用途 | |
JP2020519651A (ja) | アミン又は(チオ)アミド含有lxrモジュレーター | |
EP2098226A1 (de) | AKAP-PKA-Interaktionshemmer zur Anwendung in der Behandlung von Herzkrankheiten | |
KR20180003545A (ko) | 질환의 치료를 위한 융합된 비시클릭 화합물 | |
JP2514163B2 (ja) | ピリミドン誘導体及び類似化合物を含有する、喘息又は炎症性気道疾患の治療用医薬組成物 | |
JP2009504692A (ja) | 新規4−アミノ−チエノ[3,2−c]ピリジン−7−カルボン酸アミド | |
CN106974899B (zh) | 抗凝血化合物及其用途 | |
ES2309567T3 (es) | Derivados de imidazopiridinas como inhibidores de no-sintasa inducible. | |
CN110903224A (zh) | 一种芳基磺酰胺类化合物、其制备方法、药物组合物及用途 | |
US7355055B2 (en) | Compounds for treatment of lipase-mediated diseases | |
US10822333B2 (en) | Pyridopyrimidines derivatives compounds | |
WO2007010546A1 (en) | Compounds for treatment of lipase-mediated diseases | |
KR20200092971A (ko) | 페르옥시솜 증식제 응답성 수용체 활성화제 | |
EP3725781B1 (de) | Kristall und salz der 4-(naphthalen-1-yl)-4h-1,2,4-triazolverbindung und verfahren zu seiner herstellung | |
TW200424195A (en) | Pyrazine compounds as CRF modulators | |
US4608381A (en) | Antiinflammatory 2-(trifluoroethylsulfonyl)benzimidazoles | |
JPS59104378A (ja) | カルボスチリル誘導体 |